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Abstract
Background: Staphylococcus aureus (SA) is the most prevalent organism infecting the respiratory tract of CF
children, and remains the second most prevalent organism in CF adults. During early childhood, SA infections are
associated with pulmonary inflammation and decline in FEV1, but their clinical significance in adult CF patients is
poorly characterized.
Methods: We conducted a retrospective cross-sectional study to determine the association between airway
microbiology and clinical outcomes (FEV1, rate of pulmonary exacerbations, CRP levels and clinical scores).
Results: In a cohort of 84 adult CF patients, 24 % were infected with SA only, 60 % were infected with PA, and
16 % had neither PA nor SA. CF patients with SA experienced fewer pulmonary exacerbations and lower CRP levels
than those with PA.
Conclusion: In adult CF patients, SA infections alone, in the absence of PA, are a marker of milder disease.
Keywords: Cystic fibrosis, Microbiology, Staphylococcus aureus, Pseudomonas aeruginosa, Lung function, Pulmonary
exacerbation, Retrospective cohort
Background
Pulmonary disease is the primary cause of morbidity and
mortality in patients with cystic fibrosis (CF). Most pa-
tients experience acute symptoms during episodes of
pulmonary exacerbations, and develop progressive lung
disease caused by both chronic airway infections and
host inflammation [1]. While it is increasingly recog-
nised that CF airway infections are polymicrobial,
Pseudomonas aeruginosa (PA) and Staphylococcus aureus
(SA) are the most prevalent organisms [2, 3]. PA, the
dominant airway pathogen, chronically infects up to 60–
75 % of adult CF patients [4], and is strongly associated
with inflammation, decline in lung function and increased
mortality [1, 5–7]. SA, on the other hand, is the most
prevalent organism during childhood, and often the first
one isolated in CF children [4, 8].
The overall prevalence of SA infections has increased
over time, both with methicillin sensitive (MSSA) and
methicillin resistant (MRSA) SA [4, 9]. Several studies
have examined the clinical impact of SA infections, but
all have focused on infants and children [10–14]. In the
pre-antibiotic era, SA was a major cause of death in CF
children. In more recent studies, SA infection in young
children is associated with a decline in lung function
[11, 12], as well as increased markers of pulmonary in-
flammation [15, 16]. Consequently, antibiotic therapy to
eradicate SA is used in some centers, but its routine use
remains controversial [10, 17–20]. As patients transition
from adolescence into adulthood, the prevalence of SA
decreases gradually but remains significant, with over
40 % of adults harbouring SA [4]. In older children, SA
infections are not consistently associated with poor
prognosis, but perhaps even better survival post-
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transplantation, as SA infection prior to transplantation
is an independent factor associated with improved sur-
vival [21, 22]. The clinical significance of SA in adult CF
patients remains unknown.
We carried out a retrospective cross-sectional study to
examine the association between airway infection (SA
alone, PA, or neither) and lung function (FEV1 % pre-
dicted) as well as pulmonary exacerbation rate. We also
examined several secondary outcomes, namely plasma
C-reactive protein (CRP) and clinical scores.
Methods
Study design
This retrospective cross-sectional cohort study included
all patients followed at the Montreal Chest Institute
(McGill University Health Centre, QC, Canada) Adult
CF clinic who were alive in January 2012. Inclusion cri-
teria were as follows: age >18 years old; diagnosis of CF;
at least one sputum microbiology culture; at least one
routine visit between January 2011 and February 2013.
The baseline visit was defined as the first routine visit
during which the patient was in a stable clinical condi-
tion within the study period. A stable clinical condition
was defined as a period of at least 28 days without intra-
venous (IV) or oral antibiotics (excluding chronic anti-
biotic treatment). Patients were excluded if they had no
routine visit during our study period (n = 6) or were col-
onized with Burkholderia cepacia complex (n = 1). All
study participants provided written informed consent.
The study was approved by the Research Ethics Board of
the McGill University Health Center.
Demographic and clinical data
The demographic and clinical data were collected from
the CF clinic database, a prospective database of all
clinic patients and visits. Demographic data included age
and sex. The body mass index (BMI) was calculated
from the weight and height. Spirometry, including forced
expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC) expressed as a percentage of predicted values,
was performed according to the American Thoracic So-
ciety standards [23] and was measured at the baseline
visit for this study. Pulmonary exacerbations are epi-
sodes of clinical deterioration diagnosed clinically by the
treating physician, defined as episodes requiring IV anti-
biotic treatment at home or in the hospital. The exacer-
bation rate was calculated using the number of
pulmonary exacerbations during the calendar year.
We used the Matouk clinical score, a previously de-
scribed and validated measure of CF disease activity
[24, 25]. The total clinical score includes key manifesta-
tions of CF disease with clinical (signs and symptoms),
radiographic (chest radiographic findings), pulmonary
function and complication subscores as previously
described [24, 25]. For this study, we excluded the
microbiology subscore (originally described in [24, 25])
to avoid a collinearity effect between the total clinical
score and the airway infection status. The total clinical
score (out of total of 95 points) is scaled to indicate
more severe diseases with lower scores.
Microbiology and laboratory data
All spontaneously expectorated sputum samples col-
lected from patients, during both routine and non-
routine visits as well as hospitalisations, were analyzed
by the McGill University Health Centre clinical micro-
biology laboratory according to standard protocols for
CF samples. Briefly, sputum samples were cultured on
sheep blood agar, MacConkey agar, and B. cepacia agar
plates (BD), and the presence of PA, SA, and B. cepacia
were confirmed through standard biochemical testing.
The patients’ infection status was determined based on
the microbiology results of all sputum cultures collected
during the calendar year of the baseline visit, including
both routine and exacerbation visits. Patients were de-
fined as infected with PA and/or SA if ≥50 % of their
sputum samples were positive. In the case of insufficient
samples, sputum microbiology results from the previous
calendar year were used. No differentiation was made
between MSSA and MRSA infections in our primary
analyses because of the small number of patients with
MRSA in our clinic (n = 4). Plasma C-reactive protein
(CRP) levels were measured from plasma samples col-
lected during the baseline visit using ELISA.
Statistical analysis
Continuous variables (age, body mass index, FEV1 and
FVC % predicted, clinical score and subscores, and CRP)
were compared among the different infection groups
using one-way analysis of variance (ANOVA) or stu-
dent’s t-test. Post-hoc analysis was done in conjunction
with ANOVA using Tukey’s test. Categorical variables
(sex) were compared using the Mantel-Haenszel chi-square
test. Differences in exacerbation rate and hospitalization
rate were calculated using Poisson regression. P-values
of ≤0.05 were considered statistically significant. To as-
sess the association between airway infection and the
patient’s clinical status, we used FEV1 % predicted and
exacerbation rate as primary outcomes, and plasma
CRP and clinical scores as secondary outcomes. Multi-
variable analyses included variables (age and sex) deter-
mined a priori. Linear regression was used for
continuous outcomes (FEV1 % predicted, plasma CRP
and clinical scores), and Poisson regression was used
for count data outcomes (exacerbation rate). Variables
were tested for collinearity using a correlation matrix.
In multivariable analyses, the infection category “PA”
was used as a reference group, as this was the largest
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group. Statistical analyses were conducted using SAS
9.2 statistical package (SAS Institute Inc., USA).
Results
A total of 91 adult patients were followed at the Montreal
Chest Institute CF clinic during the study period, and 84
patients were included in this study. We analyzed the
microbiology of a total of 366 sputum samples collected
during the study period (average 4.3 samples per patient):
37 % of samples were positive for SA (including n = 4 for
MRSA), and 70 % were positive for PA. The study patients
were classified into one of 3 groups based on their PA and
SA airway infection status, namely “PA” (n = 50; 59 %),
“SA only” (n = 20; 24 %), and “no PA/SA” (n = 14; 17 %)
for patients infected with neither PA nor SA. The patients’
demographic and clinical outcomes for each group are
presented in Table 1. The identification of microorgan-
isms other than PA and SA, namely Aspergillus and
Stenotrophomonas maltophilia, in each of the 3 groups
are summarized in Additional file 1: Table S1. The pa-
tients in the different infection groups were similar in
age, sex and BMI. There was a trend suggesting that
“PA” patients were associated with worse FEV1 and
FVC % than “SA only” and “no PA/SA” patients. In uni-
variate analyses, the infection groups significantly dif-
fered in their exacerbation rate, clinical scores and CRP
levels. Across these clinical outcomes, “SA only” pa-
tients were similar to “no PA/SA” patients, while “PA”
patients experienced the highest rate of exacerbation,
CRP and lowest clinical score.
To adjust for confounding factors that affect CF dis-
ease such the age and sex, we next performed multivari-
able analyses. Although there was a trend suggesting
that “no PA/SA” patients had better FEV1 compared to
“PA” patients using a linear regression model, we found
no statistically significant association between airway
Table 1 Clinical characteristics of cohort patients based on infection status
No PA/SA SA only PA P-value
n (%) 14 (16.7 %) 20 (24.1 %) 50 (59.5 %) -
Age (years) 30.9 (±13.7) 28.5 (±12.2) 35.6 (±12.8) 0.097
Female sex (%) 8 (57.1 %) 9 (45.0 %) 25 (50.0 %) -
Number of sputum samples 3.6 (±3.7) 3.3 (±2.5) 5.5 (±4.3) 0.055
Number of routine visits 6.6 (±5.3) 4.4 (±3.6) 7.9 (±6.9) 0.096
BMI 21.1 (±2.5) 22.5 (±3.5) 22.0 (±4.5) 0.608
FEV1 (% predicted) 70.9 (±21.0) 66.5 (±22.1) 56.3 (±27.2) 0.096
FVC (% predicted) 85.8 (±22.1) 82.8 (±19.3) 72.7 (±26.3) 0.110
Exacerbation rate 0.43 0.20 1.20 <0.02*
Hospitalization rate 0.21 0.15 1.30 <0.10
Total clinical score (out of 95) 71.1 (±14.1) 68.6 (±10.9) 60.8 (±14.6) 0.017a
Clinical subscore (out of 45) 35.3 (±4.6) 35.1 (±3.3) 33.0 (±3.8) 0.048*
Radiographic subscore (out of 25) 18.9 (±4.0) 17.7 (±2.9) 15.9 (±2.7) 0.003a
Pulmonary function subscore (out of 25) 18.5 (±5.1) 18.0 (±5.1) 15.3 (±6.2) 0.081
Complication subscore (out of 37) 1.5 (±2.3) 2.3 (±2.6) 3.4 (±4.2) 0.185
CRP† 2.50 (±3.5) 4.8 (±3.2) 10.6 (±10.0) 0.005a,b
SA = Staphylococcus aureus; PA = Pseudomonas aeruginosa; SD = standard deviation; BMI = body mass index; FEV1 = forced expiratory volume in 1 s; FVC = forced
vital capacity; CRP = C-reactive protein
Data are expressed as mean (± SD) or number (% total), except for the exacerbation and hospitalization rates expressed as mean rates calculated by Poisson regression
P-values were determined using the ANOVA or Chi-squared test. For exacerbation rate and hospitalization rate, P-values were determined by a comparison with a
null model
Comparisons between groups were done using Tukey’s test. Tukey’s test reported the following differences: ap < 0.05, “No PA/SA” vs. “PA”
bp < 0.05, “SA only” vs. “PA”
†CRP data was only available in a subset of patients and results in Table 2 were collected from the different groups are as follows: Group No PA/SA: 11/14;
Group SA only: 16/20; Group PA: 35/50
Table 2 Association between infection status and FEV1 %
Crude Adjusted
Regression 95 % CI P-value Regression 95 % CI P-value
Coefficient Coefficient
No PA/SA 14.6 −0.4 to 29.5 0.059 14.0 −1.2 to 29.3 0.074
SA only 10.2 −2.9 to 23.2 0.131 9.2 −4.4 to 22.8 0.187
PA 0 Reference - 0 Reference -
Regression coefficients were calculated using a linear regression. The adjusted model includes age and sex as covariates
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infection status and FEV1, (Table 2). Next, we compared
the exacerbation rate of the different airway infection
groups using a Poisson regression model, as presented
in Table 3. Compared to “PA” patients, both “SA only”
and those with “no PA/SA” were associated with a sig-
nificantly lower rate of pulmonary exacerbation. In the
adjusted model, “SA only” patients were associated with
a relative risk of 0.2 (95 % CI [0.1-0.4]) compared to
“PA” patients. We also examined several secondary out-
comes, namely CRP (Table 4) and the modified Matouk
total clinical score (Table 5), a clinical subscore (which
quantifies signs, symptoms and complications of CF dis-
ease). The “SA only” patients were associated with re-
duced CRP levels (in both unadjusted and adjusted
models) and higher clinical scores (unadjusted model
only) compared to “PA” patients. Interestingly, patients
with “no PA/SA” showed similar results to “SA only” pa-
tients. Taken together, these analyses suggest that “SA
only” patients overall have significantly better clinical
outcomes than “PA” patients.
In all four crude models, “no PA/SA” and “SA only”
groups had better total clinical scores and subscores
than the reference “PA only” group. These trends were
also observed in the adjusted models, although only the
comparison between “no PA/SA” and “PA only” groups
remained statistically significant. Consistent with the ob-
servation that patients infected with “no PA/SA” and
“SA only” had less active disease than those infected
with “PA only”, their plasma CRP levels were lower in
both crude and adjusted models.
Among PA infected patients in the “PA” group, 10 out
of 50 were co-infected with both PA and SA. The demo-
graphic and clinical characteristics of patients based on
their infection group, with the “PA only” and “PA + SA”
groups separated, are presented in the Additional file 1:
Table S2, and both groups showed no significant differ-
ences (Table 6). In order to determine whether including
the “PA + SA” patients to the “PA” group had a
significant effect on our results, we excluded the “PA +
SA” patients and repeated the univariate and multivari-
ate analyses. As shown in the Additional file 1: Table S3
to S6, all results were similar. Furthermore, 4 out of 84
patients (4.8 %) in our cohort were MRSA, and all were
co-infected with both PA and SA. The results of all uni-
variate and multivariate analyses remained unchanged
after exclusion of the MRSA patients (data not shown).
Discussion
To date, studies reporting on SA infections have exclu-
sively focused on CF children where the prevalence of
SA infections is higher. In children under 12 months,
27 % of bronchoalveolar lavage fluids are positive for SA
[26]. The prevalence of SA increases during childhood
and is highest in children 6 to 10 years old [4]. In young
children under the age of 2, SA infections are associated
with a decline in lung function [11, 12, 15, 27, 28]. In
those under 7, SA infections are associated with pul-
monary inflammation, increased neutrophil counts, ele-
vated IL-8, and free neutrophil elastase on BAL [15].
Consequently, antibiotic therapies can be used to pre-
vent or eradicate SA [29–31], but their routine use re-
mains controversial [10, 17–19].
In contrast to children, the clinical significance of SA
infections in adult is not established. The presence of SA
infections may in fact be a marker of less severe disease,
as it could represent the absence of PA. Reports that SA
infections in older children are associated with better 5-
year survival following transplantation suggest that this
may be the case [21, 22]. In our cohort of adult CF pa-
tients, 24 % of patients are colonized with SA only, with-
out PA. Patients with SA were associated with lower
rates of pulmonary exacerbations and CRP than those
with “PA”, suggesting that infection with SA is a marker
of less severe disease. Interestingly, we did not identify
any significant association between the airway infection
status and lung function (FEV1 and FVC). Although
Table 3 Association between infection status and exacerbation rate
Crude Risk Ratio 95 % CI P-value Adjusted Risk Ratio 95 % CI P-value
No PA/SA 0.4 0.4 to 0.8 0.016 0.3 0.1 to 0.8 0.011
SA only 0.2 0.1 to 0.5 0.0005 0.2 0.1 to 0.4 0.0004
PA 1.0 Reference - 1.0 Reference -
Risk ratios were calculated using a Poisson regression. The adjusted model includes age and sex as covariates
Table 4 Association between infection status and C-reactive protein
Crude Adjusted
Regression 95 % CI P-value Regression 95 % CI P-value
Coefficient Coefficient
No PA/SA −8.0 −13.4 to −2.7 0.005 −8.1 −13.5 to −2.6 0.005
SA only −5.8 −10.5 to −1.1 0.019 −5.8 −10.8 to −0.8 0.026
PA 0 Reference - 0 Reference -
Regression coefficients were calculated using a linear regression. The adjusted model includes age and sex as covariates
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FEV1 is the most commonly used clinical outcome in
studies of CF lung disease due to its association with mor-
tality and quality of life [32–35], it may not be as sensitive
to the disease activity as the rate of pulmonary exacerba-
tions and clinical scores, particularly in light of our small
sample size for the “no PA/SA” and “SA only” groups.
It is also worth noting that among those infected with
PA, 20 % (n = 10) were co-infected with both PA and
SA. In children, several studies have reported that PA +
SA co-infections are associated with diminished survival,
greater decline in lung function and increased airway in-
flammation in CF children [11, 15, 16]. Unfortunately,
the small size of this group in our study precluded any
meaningful subgroup analyses. However, we compared
patients with only PA and those with PA + SA and found
no significant differences in demographic or clinical
parameters. Our findings also did not differ when the
PA + SA patients were excluded from our analyses.
In the face of the global rise in MRSA, the prevalence
of MRSA has also increased in many CF clinics [36, 37].
Methicillin-resistant SA (MRSA) is present in 4.1 % of
CF patients in Canada [38] and has been associated with
faster decline in lung function than methicillin-
susceptible SA (MSSA) [39]. It has also been shown to
be a risk factor for failure to recover from exacerbation
[40], and persistent infection has been linked to in-
creased mortality [39]. The prevalence of MRSA in our
cohort was 4.8 % and the small number of MRSA+ pa-
tients precluded any subgroup analyses. However, our
results were unchanged when we performed the analysis
of our cohort excluding the MRSA patients. Finally, our
study and others likely underestimate the true preva-
lence of SA infection. Standard clinical laboratories typic-
ally do not detect small colony variant SA strains that are
slow growing [41] which may be associated with a greater
decline in FEV1 in CF children [42] and more severe lung
disease [43].
Conclusion
Our study suggests that, in contrast to children, the
presence of SA in CF adults, in the absence of PA, is a
marker of milder lung disease.
Additional file
Additional file 1: Table S1. Sputum microbiology for other
microorganisms in sputum cultures
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